Focus on human microbiome to fight liver cirrhosis

22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.

Learn more

MICROB-PREDICT at ILC 2019

Jonel Trebicka and Minneke Coenraad presented the project's objectives, its consortium members, and the expected impact of MICROB-PREDICT at the International Liver Congress (ILC) in Vienna, Austria. The annual congress is organised by EASL.

More news

Copenhagen, 11 September 2019

The MICROB-PREDICT Steering Committee met for the second time in Copenhagen. We are happy to summarize that the project is ahead of schedule.

More events